Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial
Shaukat Ali, Syed Muneeb Uddin, Elisha Shalim, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100926-100926
Open Access | Times Cited: 53

Showing 26-50 of 53 citing articles:

Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
Hillary A. Vanderven, Stephen J. Kent
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 4
In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors
Gabriel Rojas-Jiménez, Daniela Solano, Álvaro Segura, et al.
Frontiers in Medical Technology (2022) Vol. 3
Open Access | Times Cited: 7
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 4
Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials
Dimitrios Sagris, Matilda Florentin, Panagiotis Tasoudis, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 22, pp. 5366-5366
Open Access | Times Cited: 9
Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic
Jannis Kountouras, Dimitra Gialamprinou, Georgios Kotronis, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 309-309
Open Access | Times Cited: 6
Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial
Andrea Alemany, Pere Millat-Martínez, Marc Corbacho-Monné, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101898-101898
Open Access | Times Cited: 3
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Junzheng Wu, Huichuan Yang, Ding Yu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 3
Passive antibody therapy in emerging infectious diseases
Xiaoming Yang
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1117-1134
Closed Access | Times Cited: 3
Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing’s Syndrome: A Case Report and Review of Literature
Bojana Popović, Aleksandra Radovanović Spurnić, Jelena Veličković, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 5
Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis
Zhangcheng Fei, Zhongsheng Chen, Xi Du, et al.
Transfusion Medicine and Hemotherapy (2022) Vol. 49, Iss. 6, pp. 388-400
Open Access | Times Cited: 4
Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis
Meixuan Li, Yan-fei Li, Xin Xing, et al.
Inflammopharmacology (2023) Vol. 32, Iss. 1, pp. 335-354
Closed Access | Times Cited: 2
Is SARS‐CoV‐2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody‐based therapeutics?
Daniele Focosi, Massimo Franchini, Liise‐anne Pirofski, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 4
Closed Access | Times Cited: 5
High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
Cynthia So‐Osman, Sarah J Valk
The Lancet (2022) Vol. 399, Iss. 10324, pp. 497-499
Open Access | Times Cited: 3
Brixia Score in Outcomes of Alpha versus Delta Variant of Infection in Pregnant Critical COVID-19 Patients
Roxana Covali, Demetra Socolov, Ioana Păvăleanu, et al.
International Journal of Translational Medicine (2022) Vol. 2, Iss. 1, pp. 66-77
Open Access | Times Cited: 3
Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks
Tihana Kurtović, Sanda Ravlić, Adela Štimac, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 3
Effect of intravenous immunoglobulin on mortality in hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized controlled trials
Dinesh Sangarran Ramachandram, Chia Siang Kow, Syed Shahzad Hasan, et al.
Health Science Reports (2024) Vol. 7, Iss. 7
Open Access
Understanding the relevance of immunological markers in severe multisystem inflammatory syndrome in children through machine learning
Reetika Malik Yadav, Rahul Gupta, Nidhi Desai, et al.
Journal of Laboratory Physicians (2024) Vol. 16, pp. 399-412
Open Access
Towards personalized and rational use of immunoglobulins amid expanding indications and shortages
Hadi Goubran, Gaafar Ragab, Jerard Seghatchian, et al.
Transfusion and Apheresis Science (2024) Vol. 63, Iss. 5, pp. 103987-103987
Closed Access
Selection of plasma donors for the production of anti-SARS-CoV-2 immunoglobulin-based therapies: Strategies for quantitative antibody measurements
Bruno Deltreggia Benites, Carolina Costa-Lima, Fernanda Batista Rosa Pinto, et al.
Transfusion and Apheresis Science (2022) Vol. 61, Iss. 6, pp. 103513-103513
Open Access | Times Cited: 2
Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis
Rong-Juan Dai, Minjie Hu, Haibo Tang, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 2
A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza
Catherine Kimber, Abigail Lamikanra, Louise Geneen, et al.
Transfusion Medicine (2022) Vol. 33, Iss. 1, pp. 26-38
Open Access | Times Cited: 2
COVID-19 Advanced Care
Evangelia Fouka, Ioannis Kalomenidis, Niki Gianniou, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 11, pp. 1082-1082
Open Access | Times Cited: 2
Development and Characterization of anti-SARS-CoV-2 Intravenous Immunoglobulin from COVID-19 Convalescent Plasma
Mikhail Razumikhin, T. I. Smolyanova, А. М. Николаева, et al.
Immunotherapy (2022) Vol. 14, Iss. 14, pp. 1133-1147
Open Access | Times Cited: 1
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial
Shaukat Ali, Elisha Shalim, Farah Farhan, et al.
Trials (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 1

Scroll to top